论文部分内容阅读
在恶性肿瘤患者中,常伴有凝血、纤溶、血小板及血管功能异常导致的出血或血栓形成。这些异常也参与肿瘤转移。本文介绍近年来肿瘤与凝血方面的临床及基础研究进展,以有助于对肿瘤治疗及肿瘤患者凝血机制异常的了解。恶性肿瘤的临床出血与血栓形成 90%肿瘤转移患者和50%恶性肿瘤患者存在着止血功能异常。 10%恶性肿瘤患者有出血症状,主要原因是化疗导致的血小板减少症,而肿瘤细胞的组织侵袭及播散性血管内凝血[DIC]也是原因之一。急性白血病的出血发生率达18～60%,占急性白血病死因10%。
In patients with malignant tumors, often accompanied by coagulation, fibrinolysis, platelet and blood vessel dysfunction caused by bleeding or thrombosis. These abnormalities are also involved in tumor metastasis. This article describes the clinical and basic research advances in cancer and coagulation in recent years in order to contribute to the understanding of cancer therapy and the abnormalities of coagulation mechanisms in cancer patients. Clinical Bleeding and Thrombosis in Tumors 90% of patients with tumor metastases and 50% of patients with malignancies have hemostatic abnormalities. Hemorrhagic symptoms occur in 10% of patients with malignancy, mainly due to chemotherapy-induced thrombocytopenia, which is also one of the reasons for the tissue invasion of tumor cells and disseminated intravascular coagulation [DIC]. Acute leukemia bleeding rate of 18 to 60%, accounting for 10% of the cause of death of acute leukemia.